Core Viewpoint - Inotiv, Inc. will release its financial results for the fiscal 2026 first quarter on February 9, 2026, before the market opens, and will host a conference call to discuss these results [1]. Company Overview - Inotiv, Inc. is a leading contract research organization that specializes in nonclinical and analytical drug discovery and development services, as well as research models and related products [3]. - The company's focus is on enhancing the efficiency and data quality of drug and medical device development while reducing costs associated with bringing new products to market [3]. - Inotiv is dedicated to supporting research and development objectives, aiming to help researchers maximize the potential of their projects for a healthier and safer world [3].

Core Insights - Inotiv, Inc. reported a 5.9% increase in revenue for Q4 FY 2025, reaching $138.1 million, and a 4.5% increase for FY 2025, totaling $513.0 million [1][12] - The operating loss for Q4 FY 2025 decreased by 48.5% to $6.8 million, while the annual operating loss for FY 2025 decreased by 64.2% to $30.9 million [1][6] Financial Performance - Q4 FY 2025 revenue was $138.1 million, up from $130.4 million in Q4 FY 2024, driven by a $7.1 million increase in DSA revenue and a $0.7 million increase in RMS revenue [7][10] - FY 2025 revenue increased to $513.0 million from $490.7 million in FY 2024, with RMS revenue up by $14.5 million and DSA revenue up by $7.8 million [12][13] - Consolidated net loss for Q4 FY 2025 was $8.6 million, or 6.2% of total revenue, compared to a loss of $18.9 million, or 14.5% of total revenue, in Q4 FY 2024 [7][10] - Adjusted EBITDA for Q4 FY 2025 was $11.8 million, or 8.5% of total revenue, compared to $5.4 million, or 4.1% of total revenue, in Q4 FY 2024 [7][10] Segment Performance - DSA revenue for Q4 FY 2025 was $51.6 million, a 15.7% increase from $44.6 million in Q4 FY 2024, while RMS revenue was $86.5 million, a slight increase of 0.8% from $85.8 million [2][32] - For FY 2025, DSA revenue totaled $187.9 million, up 4.3% from $180.1 million in FY 2024, and RMS revenue reached $325.1 million, a 4.7% increase from $310.6 million [2][12] Operational Highlights - The book-to-bill ratio for Q4 FY 2025 was 1.08x for the DSA services business, indicating strong demand [7] - DSA backlog increased to $138.2 million at September 30, 2025, up from $129.9 million at the same time last year [7] Management Commentary - The CEO emphasized the focus on improving cash flow, margins, and client metrics, noting that the revenue increase was in line with expectations [3][4] - The company remains committed to client satisfaction and delivering high-quality products and services, with a significant increase in DSA net awards by approximately 61% year-over-year [4]

Core Insights - Inotiv achieved a remarkable revenue growth of 448% from fiscal year 2021 to fiscal year 2024, earning a spot at 182 on the Deloitte Technology Fast 500™ ranking [1][2] - The company's success is attributed to its client-focused approach, strategic acquisitions, and the development of complementary services that enhance client support [2] - Inotiv has been recognized as a Deloitte Technology Fast 500™ winner for three consecutive years, reflecting both client trust and team dedication [2] Company Overview - Inotiv, Inc. is a leading contract research organization that provides nonclinical and analytical drug discovery and development services, focusing on improving efficiency and reducing costs in bringing new drugs and medical devices to market [5] - The company aims to support researchers in realizing the full potential of their critical research and development projects, contributing to a healthier and safer world [5] Industry Context - The Deloitte Technology Fast 500™ ranks the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America based on percentage revenue growth [3] - The 2025 rankings highlight a mix of established leaders and new innovators, with private companies showing significant agility and growth potential in competitive markets [2][3]

Core Viewpoint - Inotiv, Inc. will release its financial results for the fiscal year 2025 on December 3, 2025, and will host a conference call to discuss these results [1]. Company Overview - Inotiv, Inc. is a leading contract research organization that specializes in nonclinical and analytical drug discovery and development services, as well as research models and related products [3]. - The company's focus is on enhancing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market [3]. - Inotiv is dedicated to supporting research and development objectives, aiming to help researchers maximize the potential of their projects while contributing to a healthier and safer world [3].

Core Insights - Inotiv, Inc. anticipates fourth quarter 2025 revenue between $137.5 million and $138.5 million, reflecting a year-over-year improvement and aligning with expectations [1][2] - The company expects full year 2025 revenue to be in the range of $512.5 million to $513.5 million [1][6] - The Discovery and Safety Assessment (DSA) services business experienced a 60% growth compared to the same period last year, with a book-to-bill ratio of approximately 1.08x for Q4 FY 2025 [2][6] Preliminary Financial Results - Preliminary expected revenue for Q4 FY 2025 is projected at $137.5 million to $138.5 million [1][6] - Full year 2025 revenue is anticipated to be between $512.5 million and $513.5 million [1][6] - DSA backlog is expected to be approximately $138.0 million as of September 30, 2025, an increase from $129.9 million a year prior [6] Company Presentation - Robert Leasure Jr., President and CEO, will present at the Jefferies Global Healthcare Conference on November 18, 2025, at 11:00 AM GMT [4] - The presentation will be accessible via a live webcast, with a replay available on the company's website [4] Company Overview - Inotiv, Inc. is a leading contract research organization focused on nonclinical and analytical drug discovery and development services [5][7] - The company aims to enhance efficiency, improve data quality, and reduce costs associated with bringing new drugs and medical devices to market [5]

Core Insights - Inotiv, Inc. is actively participating in several upcoming healthcare conferences, showcasing its commitment to engaging with institutional investors and stakeholders in the healthcare sector [1][2]. Group 1: Conference Participation - Inotiv's President and CEO, Robert Leasure Jr., and CFO, Beth Taylor, will represent the company at the UBS Global Healthcare Conference on November 10-11, 2025, in Palm Beach Gardens, FL, focusing on one-on-one institutional investor meetings [2]. - The company will also present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 4:00 PM GMT/11:00 AM ET, which will include a presentation and one-on-one meetings [2]. - Additionally, Beth Taylor will participate in the Craig-Hallum Alpha Select Conference in New York, NY, on November 18, 2025, which will also be focused on one-on-one institutional investor meetings [2]. Group 2: Company Overview - Inotiv, Inc. is a leading contract research organization that specializes in nonclinical and analytical drug discovery and development services, as well as research models and related products [3]. - The company's services aim to enhance the efficiency and data quality of drug and medical device development while reducing associated costs [3]. - Inotiv is dedicated to supporting research and development objectives, contributing to the advancement of healthcare and safety [3].

Core Viewpoint - Inotiv, Inc. is actively participating in several upcoming investment conferences, showcasing its commitment to engaging with investors and promoting its services in the drug discovery and development sector [1][2]. Company Overview - Inotiv, Inc. is a leading contract research organization that specializes in nonclinical and analytical drug discovery and development services, as well as research models and related products [3]. - The company focuses on enhancing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market [3]. - Inotiv aims to support researchers in achieving their research and development objectives while contributing to a healthier and safer world [3]. Conference Participation - Inotiv's management, including President and CEO Robert Leasure Jr. and CFO Beth Taylor, will participate in the following conferences: - Baird Global Healthcare Conference on September 9, 2025, at 12:50 PM Eastern Time [2]. - H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 12:30 PM Eastern Time [2]. - Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11, 2025, with a focus on 1-on-1 institutional investor meetings [2].

Core Insights - Inotiv, Inc. reported a 23.5% increase in revenue for Q3 FY 2025, reaching $130.7 million compared to $105.8 million in Q3 FY 2024, driven by significant growth in Research Models and Services (RMS) and Discovery and Safety Assessment (DSA) segments [1][7][11] - Year-to-date revenue for FY 2025 increased by 4.0% to $374.9 million from $360.3 million in FY 2024, primarily due to higher RMS revenue [1][13][14] - The company experienced a consolidated net loss of $17.6 million in Q3 FY 2025, an improvement from a net loss of $26.1 million in Q3 FY 2024 [1][7][11] Financial Performance - Q3 FY 2025 revenue breakdown: RMS revenue increased by $21.0 million (34.1%) and DSA revenue increased by $3.9 million (8.9%) [3][11] - Adjusted EBITDA for Q3 FY 2025 was $11.6 million, or 8.9% of total revenue, compared to $0.1 million (0.1%) in Q3 FY 2024 [7][11][43] - The book-to-bill ratio for DSA services was 1.07x in Q3 FY 2025, indicating a healthy demand for services [7][11] Segment Analysis - DSA segment revenue for Q3 FY 2025 was $48.2 million, up from $44.2 million in Q3 FY 2024, while RMS segment revenue was $82.5 million, up from $61.6 million [3][34] - Year-to-date RMS revenue increased by 6.1% to $238.6 million, while DSA revenue saw a modest increase of 0.6% to $136.3 million [3][14] Management Commentary - The CEO highlighted progress towards financial goals set during the investor day in May, noting improved revenue and margins compared to the previous quarter [4][6] - The company remains focused on client satisfaction and the delivery of high-quality products and services, with a strong emphasis on operational data monitoring [5][6] Recent Developments - The SEC concluded its investigation related to non-human primate importations without recommending enforcement action against the company [14] - The company recorded a $10.0 million accrual for ongoing securities class action lawsuits, expecting to recover this amount under existing insurance policies [14]

Company Overview - Inotiv, Inc. is a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, as well as research models and related products and services [3] - The company's focus is on enhancing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market [3] Financial Results Announcement - Inotiv will release its financial results for the fiscal 2025 third quarter, which ended on June 30, 2025, on August 6, 2025, after the stock market closes [1] - A conference call will be held on the same day at 4:30 p.m. Eastern Time to discuss the financial results [1] Participation Information - Interested parties can participate in the conference call by dialing the provided numbers or accessing the live webcast through the company's website [2] - An online replay of the conference call will be available for those unable to attend the live broadcast [2]

Company Overview - Inotiv, Inc. is a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, as well as research models and related products [3] - The company's focus is on enhancing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market [3] - Inotiv aims to support discovery and development objectives while contributing to a healthier and safer world [3] Upcoming Event - Robert Leasure Jr., President and CEO of Inotiv, will present at the Jefferies Global Healthcare Conference in New York on June 4 at 3:45 p.m. ET [1] - The live webcast of the presentation will be available in the "Investors" section of Inotiv's website and will be archived for approximately 90 days [2]